Protect Infant Formula from Contamination Act

Bill Number: S. 272
Origin Chamber: Senate
Congress: 119th Congress, Session 2
Policy Area: Health
Status: Passed Senate
Latest Action: 2026-05-04: Held at the desk.
Last Updated: 2026-05-05T08:05:57Z

AI-Generated Summary

Protect Infant Formula from Contamination Act (S. 272)

Purpose

This law aims to enhance the safety of infant formula by requiring faster notifications of contamination test results and mandating reports to improve both safety and supply resiliency. It responds to risks from microorganisms like those tested under FDA regulations.

Key Provisions

Faster Notifications for Contamination (amends Section 412(e) of the Federal Food, Drug, and Cosmetic Act):
Manufacturers must notify the FDA Secretary within 1 business day of knowing about potential contamination (previously "promptly").
For confirmed positive tests of required microorganisms in production batches:
Notify FDA within 1 business day, even if product hasn't left the facility.
Consult FDA on isolating affected product, cease distribution, and dispose as directed.
Provide test results, isolates, or whole genome sequence data.
FDA must respond within 1 business day to discuss investigation and fixes.
Within 90 days, FDA confirms the manufacturer's investigation (reviewing test methods and contamination risks); manufacturers supply electronic documents for review or inspection.
Reporting Requirements (adds new Section 412(n)):
Progress Report (180 days after enactment): Updates on FDA's January 2025 strategy for infant formula resiliency, including needed authorities/resources and recall-driven changes.
Quarterly Supply Reports (starting 270 days after enactment, for 5 years): Current data like in-stock rates to key congressional committees.
Consultations: FDA works with USDA and others on immediate needs and long-term supply strength.
Supply Adequacy Reports (1, 3, and 5 years after enactment): Engage stakeholders on best practices (e.g., frequent testing for contaminants like botulism, bracketing suspect products); recommend manufacturer changes for better supply and safety.

Significant Changes to Existing Law

Tightens notification timelines from vague "promptly" to strict 1-business-day deadlines.
Introduces mandatory actions for confirmed positives (notification, isolation, data sharing) not previously specified.
Adds FDA response obligations and 90-day confirmation process.
Creates new ongoing reporting on safety progress and supply chain, absent before.

Potential Impacts

Government Agencies: Increases FDA workload for rapid responses, confirmations, and reports; fosters coordination with USDA.
Citizens: Faster detection/isolation of contaminated formula reduces health risks to infants (e.g., from bacteria causing serious illness).
Supply Chain: Quarterly monitoring and stakeholder input could stabilize availability, preventing shortages like past recalls.
No direct international relations impact noted.

Main Stakeholders Affected

Infant Formula Manufacturers: Stricter testing notifications, investigations, and data sharing; potential practice changes.
FDA (Secretary): New response, confirmation, and reporting duties.
Congressional Committees: Receive regular updates (e.g., Health, Education, Labor, and Pensions; Agriculture).
USDA and Other Agencies: Involved in consultations.
Public and Parents: Benefit from safer, more reliable formula supply.

Notable Legal, Constitutional, or Political Implications

Legal: Strengthens enforcement under the Federal Food, Drug, and Cosmetic Act via specific timelines and documentation requirements; allows FDA inspections.
Constitutional: No apparent issues; aligns with Congress's commerce clause authority over food safety.
Political: Promotes transparency and accountability post-recalls; emphasizes evidence-based improvements without mandating new tests.

This summary was generated by AI and may contain inaccuracies. Refer to the official source document for the authoritative text.

Sponsor

Sen. Peters, Gary C. [D-MI]

Cosponsors (9)

Sen. Hoeven, John [R-ND], Sen. Collins, Susan M. [R-ME], Sen. Smith, Tina [D-MN], Sen. Shaheen, Jeanne [D-NH], Sen. Hassan, Margaret Wood [D-NH], Sen. Kaine, Tim [D-VA], Sen. Baldwin, Tammy [D-WI], Sen. Murray, Patty [D-WA], Sen. Fischer, Deb [R-NE]

Recent Actions

2026-05-04: Held at the desk.
2026-05-04: Received in the House.
2026-05-01: Message on Senate action sent to the House.
2026-04-28: Passed Senate with an amendment and an amendment to the Title by Unanimous Consent. (consideration: CR S2074-2075; text: CR S2074)
2026-04-28: Passed/agreed to in Senate: Passed Senate with an amendment and an amendment to the Title by Unanimous Consent.
2026-01-28: Placed on Senate Legislative Calendar under General Orders. Calendar No. 306.
2026-01-28: Committee on Health, Education, Labor, and Pensions. Reported by Senator Cassidy with an amendment in the nature of a substitute and an amendment to the title. Without written report.
2026-01-28: Committee on Health, Education, Labor, and Pensions. Reported by Senator Cassidy with an amendment in the nature of a substitute and an amendment to the title. Without written report.
2026-01-15: Committee on Health, Education, Labor, and Pensions. Ordered to be reported with an amendment in the nature of a substitute favorably.
2025-01-28: Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
2025-01-28: Introduced in Senate

Bill Versions

Protect Infant Formula from Contamination Act — issued 2026-04-28 — PDF (8 pages)
Protect Infant Formula from Contamination Act — issued 2025-01-28 — PDF (6 pages)
Protect Infant Formula from Contamination Act — issued 2026-01-28 — PDF (14 pages)